USA flag logo/image

An Official Website of the United States Government

Novel Self-Limiting Prothrombinase Inhibitors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43HL114261
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-096
Small Business Information
SHIFA BIOMEDICAL CORPORATION
GREAT VALLEY CORPORATE CENTER ONE GREAT VALLEY PARKWAY, SUITE 8 MALVERN, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Novel Self-Limiting Prothrombinase Inhibitors
Agency: HHS
Contract: 1R43HL114261-01
Award Amount: $347,218.00
 

Abstract:

Project Summary/Abstract Thrombosis is a primary cause of death in the US and developed world. Fatal or debilitating blood clots occur in the three major diseases of the western world: heart attacks, stroke and cancer. Two of the major drugs used therapeutically to prevent blood clots are in the top drugs causing serious adverse effects, particularly bleeding, leading to emergency room treatment of patients. Our goal is to develop new antithrombotic drugs that overcome the limitations of current marketed drugs. Our molecular target is the prothrombinase complex. To that end, we will integrate virtual (computer) screening methods and biophysical/biochemical assays to identify lead compounds that can potentially be optimized to produce novel drugs for the treatment of thrombosis. Virtual screening, which requires the availability of atomic resolution 3D structures of the target protein, provides a cost effective way to screen millions of compounds to identify just a few to be purchased and tested in a biological or biochemical assay. Our access to such 3D structures of Factor Xa makes this work possible. The specific aims of this work are to: 1. Use virtual screening methods to identify compounds that bind in the FXa-Va interface. 2. Determine the binding of compounds selected in Specific Aim 1 to FXa using biophysical assays. 3. Determine inhibitory activity of the selected compounds confirmed in Specific Aim 2 using in vitro assay systems.

Principal Investigator:

Michael N. Blackburn
610-400-1243
michael@shifabiomedical.com

Business Contact:

Sherin S. Abdel
610-400-1243
sherin@shifabiomedical.com
Small Business Information at Submission:

SHIFA BIOMEDICAL
GREAT VALLEY CORPORATE CENTER ONE GREAT VALLEY PARKWAY, SUITE 8 MALVERN, PA -

EIN/Tax ID: 120552979
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No